![]() |
|
|
Vol. 286, Issue 3, 1115-1121, September 1998
Department of Preclinical and Clinical Pharmacology, Viale G.B.
Morgagni 65, I-50134 Florence, Italy
The effects of the administration of different 5-HT4
receptor antagonists (SDZ 205557, GR 125487) and 5-HT4
receptor agonists (BIMU 1, BIMU 8) on memory processes were evaluated
in the mouse passive avoidance test. The administration of SDZ 205557 (10 mg kg
1 i.p.) and GR 125487 (10 mg kg
1
i.p.) immediately after termination of the training session produced an
amnesic effect. BIMU 1 (20 mg kg
1 i.p.) and BIMU 8 (30 mg
kg
1 i.p.), administered 20 min before the training
session, prevented the 5-HT4 receptor antagonist-induced
amnesia. In the same experimental conditions BIMU 1 (10 mg
kg
1 i.p.; 25 µg/mouse intracerebroventricularly) and
BIMU 8 (30 mg kg
1 i.p.; 30 µg per mouse
intracerebroventricularly) prevented scopolamine (1 mg
kg
1 i.p.) and dicyclomine (2 mg kg
1 i.p.)
amnesia and, at the dose of 10 and 30 mg kg
1 i.p.
respectively, prevented amnesia induced by exposure to a hypoxic
environment. At the highest effective doses, none of the drugs impaired
motor coordination, as revealed by the rota rod test, or modified
spontaneous motility and inspection activity, as revealed by the hole
board and Animex tests. The 5-HT3 antagonist ondansetron
(0.1-1 mg kg
1 i.p.) was unable to prevent scopolamine-,
5-HT4 antagonist- and hypoxia-induced amnesia. These
results suggest that the modulation of 5-HT4 receptors
plays an important role in the regulation of memory processes. On these
bases, the 5-HT4 receptor agonists could be useful in the
treatment of cognitive deficits although 5-HT4 receptor
antagonists may represent pharmacological tools for investigation of
new potential antiamnesic drugs.
This article has been cited by other articles:
![]() |
M. Orsetti, A. Dellarole, S. Ferri, and P. Ghi Acquisition, Retention, and Recall of Memory After Injection of RS67333, a 5-HT4 Receptor Agonist, Into the Nucleus Basalis Magnocellularis of the Rat Learn. Mem., September 1, 2003; 10(5): 420 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Moser, O. E. Bergis, S. Jegham, A. Lochead, E. Duconseille, J.-P. Terranova, D. Caille, I. Berque-Bestel, F. Lezoualc'h, R. Fischmeister, et al. SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matsumoto, H. Togashi, K. Mori, K.-i. Ueno, S. Ohashi, T. Kojima, and M. Yoshioka Evidence for Involvement of Central 5-HT4 Receptors in Cholinergic Function Associated with Cognitive Processes: Behavioral, Electrophysiological, and Neurochemical Studies J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 676 - 682. [Abstract] [Full Text] |
||||